Linsitinib showed significant efficacy in reducing proptosis in TED patients, with a 52% responder rate at 150mg BID. The ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Andrew G. Lee, MD, and Andrew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique ...

New features include simultaneous calculation for both eyes, access to toric and non-toric results, and improved theater view design.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Bausch + Lomb announced the commercial launch of its enVista Aspire monofocal and toric intraocular lenses (IOLs) in the ...